BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

742 related articles for article (PubMed ID: 28190259)

  • 1. Early post-transplant conversion from tacrolimus to belatacept for prolonged delayed graft function improves renal function in kidney transplant recipients.
    Wojciechowski D; Chandran S; Vincenti F
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28190259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early conversion to belatacept after renal transplantation.
    Nair V; Liriano-Ward L; Kent R; Huprikar S; Rana M; Florman SS; Delaney VB; Menon MC; Sehgal V; Miko L; Khaim R; Benvenisty A; Lerner S; Arvelakis A; Wadhera V; Ames S; Shapiro R
    Clin Transplant; 2017 May; 31(5):. PubMed ID: 28267882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor-Intolerant Graft Recipients of Kidneys From Extended-Criteria Donors.
    Le Meur Y; Aulagnon F; Bertrand D; Heng AE; Lavaud S; Caillard S; Longuet H; Sberro-Soussan R; Doucet L; Grall A; Legendre C
    Am J Transplant; 2016 Jul; 16(7):2181-6. PubMed ID: 26718625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.
    Adams AB; Goldstein J; Garrett C; Zhang R; Patzer RE; Newell KA; Turgeon NA; Chami AS; Guasch A; Kirk AD; Pastan SO; Pearson TC; Larsen CP
    Am J Transplant; 2017 Nov; 17(11):2922-2936. PubMed ID: 28544101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belatacept Conversion in an HIV-Positive Kidney Transplant Recipient With Prolonged Delayed Graft Function.
    Ebcioglu Z; Liu C; Shapiro R; Rana M; Salem F; Florman S; Huprikar S; Nair V
    Am J Transplant; 2016 Nov; 16(11):3278-3281. PubMed ID: 27328903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
    Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
    Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism.
    Schulte K; Vollmer C; Klasen V; Bräsen JH; Püchel J; Borzikowsky C; Kunzendorf U; Feldkamp T
    J Nephrol; 2017 Aug; 30(4):607-615. PubMed ID: 28540602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion to belatacept maintenance immunosuppression in HIV-positive kidney transplant recipients.
    Santeusanio A; Bhansali A; De Boccardo G; Sehgal V; Delaney V; Florman S; Shapiro R
    Clin Transplant; 2020 Oct; 34(10):e14041. PubMed ID: 32654239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
    Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
    Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of acute rejection after rescue with Belatacept by association of low-dose Tacrolimus maintenance in medically complex kidney transplant recipients with early or late graft dysfunction.
    Gallo E; Abbasciano I; Mingozzi S; Lavacca A; Presta R; Bruno S; Deambrosis I; Barreca A; Romagnoli R; Mella A; Fop F; Biancone L
    PLoS One; 2020; 15(10):e0240335. PubMed ID: 33057374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belatacept in renal transplant recipient with mild immunologic risk factor: A pilot prospective study (BELACOR).
    Leibler C; Matignon M; Moktefi A; Samson C; Zarour A; Malard S; Boutin E; Pilon C; Salomon L; Natella PA; Durrbach A; Robert T; Canoui-Poitrine F; Grimbert P
    Am J Transplant; 2019 Mar; 19(3):894-906. PubMed ID: 30582270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with belatacept rescue therapy in kidney transplant recipients.
    Brakemeier S; Kannenkeril D; Dürr M; Braun T; Bachmann F; Schmidt D; Wiesener M; Budde K
    Transpl Int; 2016 Nov; 29(11):1184-1195. PubMed ID: 27514317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abatacept as rescue immunosuppression after calcineurin inhibitor treatment failure in renal transplantation.
    Badell IR; Karadkhele GM; Vasanth P; Farris AB; Robertson JM; Larsen CP
    Am J Transplant; 2019 Aug; 19(8):2342-2349. PubMed ID: 30768841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction.
    Gupta G; Regmi A; Kumar D; Posner S; Posner MP; Sharma A; Cotterell A; Bhati CS; Kimball P; Massey HD; King AL
    Am J Transplant; 2015 Oct; 15(10):2726-31. PubMed ID: 25988397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
    Sparkes T; Ravichandran B; Opara O; Ugarte R; Drachenberg CB; Philosophe B; Bromberg JS; Barth RN
    Clin Transplant; 2019 Jun; 33(6):e13531. PubMed ID: 30866104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate.
    Abdelwahab Elhamahmi D; Heilman RL; Smith B; Huskey J; Khamash H; Kaplan B
    Transplantation; 2018 Mar; 102(3):478-483. PubMed ID: 29077658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Belatacept for Simultaneous Calcineurin Inhibitor and Chronic Corticosteroid Immunosuppression Avoidance: Two-Year Results of a Prospective, Randomized Multicenter Trial.
    Kaufman DB; Woodle ES; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
    Clin J Am Soc Nephrol; 2021 Sep; 16(9):1387-1397. PubMed ID: 34233921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
    Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
    Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.